Long-term follow up of subjects previously enrolled in a phase i, randomized, double-blind, placebo-controlled study of the safety and immunogenicity of recombinant live attenuated tetravalent…
Ended Awarded Last action
- Contract number
- 75N93021F00001
- Awardee
-
The Johns Hopkins University UEI FTMTDMBR29C7
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $74,789
Award facts
- Contract value 100% obligated
- $74,789.32 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- PSC
- AJ12 General Science And Technology R&D Services; General Science And Technology; Applied Research
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost No Fee
- Place of performance
- Baltimore, MD 21218, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | -$41,595 | |
| Change Order | $0 | |
| Original award | $116,384 |
About this award
The National Institute of Allergy and Infectious Diseases issued a $74,789.32 delivery order to The Johns Hopkins University on September 17, 2021, to de-obligate unexpended and expiring fiscal year 2021 funding in support of long-term follow-up activities for subjects previously enrolled in a phase I, randomized, double-blind, placebo-controlled study of the safety and immunogenicity of recombinant live attenuated tetravalent dengue virus vaccine admixtures in healthy adults.
The order is priced on a cost–no-fee basis with an ultimate completion date of March 31, 2022. Place of performance is Baltimore, MD. No set-aside was used. The order was issued to de-obligate funds in accordance with 31 U.S.C. Section 1552(a) in preparation for the September 30, 2026 closing of the period of availability for these fiscal year funds.
Description
Long-term follow up of subjects previously enrolled in a phase i, randomized, double-blind, placebo-controlled study of the safety and immunogenicity of recombinant live attenuated tetravalent dengue virus vaccine admixtures in healthy adults
Quick answers
Who was awarded contract 75N93021F00001?
75N93021F00001 was awarded to The Johns Hopkins University by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on September 17, 2021.
How much is contract 75N93021F00001 worth?
The government has obligated $74,789 on 75N93021F00001.
Is contract 75N93021F00001 an order under another contract?
Yes. 75N93021F00001 is a delivery order under 75N93019D00031, an indefinite delivery contract.
Was contract 75N93021F00001 competed?
The extent of competition for 75N93021F00001 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award